Access cutting-edge colorectal cancer treatment through this clinical trial at a research site in New Brunswick. Study-provided care at no cost to qualified participants.
Access colorectal cancer specialists in New Brunswick at no cost
This study follows strict safety protocols and ethical guidelines
All study-related colorectal cancer treatment provided free
This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)
Sponsor: Rutgers, The State University of New Jersey
Check if you qualify for this colorectal cancer clinical trial in New Brunswick, NJ
If you're searching for colorectal cancer treatment options in New Brunswick, NJ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Brunswick research site is actively enrolling participants for this clinical trial. You'll receive care from experienced colorectal cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.